|
1
|
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
|
J Clin Oncol
|
1998
|
2.52
|
|
2
|
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
|
Eur J Cancer
|
2002
|
2.34
|
|
3
|
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
|
J Clin Oncol
|
1996
|
2.17
|
|
4
|
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
|
J Clin Oncol
|
1995
|
1.49
|
|
5
|
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
|
Ann Oncol
|
2005
|
1.33
|
|
6
|
Immunoscintigraphy of colon carcinoma.
|
J Nucl Med
|
1984
|
1.31
|
|
7
|
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
|
Br J Cancer
|
2003
|
1.25
|
|
8
|
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
|
J Clin Oncol
|
1996
|
1.25
|
|
9
|
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
|
Eur J Cancer
|
2003
|
1.24
|
|
10
|
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
|
Cancer
|
1990
|
1.15
|
|
11
|
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
|
Br J Cancer
|
2011
|
1.14
|
|
12
|
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours.
|
Ann Oncol
|
2003
|
1.10
|
|
13
|
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
|
Ann Oncol
|
2001
|
1.08
|
|
14
|
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
|
J Clin Oncol
|
2002
|
1.07
|
|
15
|
Single-agent gemcitabine is active in previously treated metastatic breast cancer.
|
Oncology
|
2001
|
1.07
|
|
16
|
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
|
Ann Oncol
|
2011
|
1.03
|
|
17
|
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
|
Ann Oncol
|
2004
|
1.01
|
|
18
|
Immunoscintigraphy of recurrences of gynecologic carcinomas.
|
J Nucl Med
|
1987
|
1.01
|
|
19
|
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
|
Rev Neurol (Paris)
|
2008
|
1.01
|
|
20
|
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.
|
Ann Oncol
|
2012
|
0.99
|
|
21
|
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
|
Ann Oncol
|
2006
|
0.98
|
|
22
|
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.
|
Br J Cancer
|
2004
|
0.96
|
|
23
|
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
|
J Clin Oncol
|
1995
|
0.95
|
|
24
|
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.
|
Eur J Cancer
|
2002
|
0.95
|
|
25
|
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
|
Eur J Cancer
|
1999
|
0.95
|
|
26
|
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
|
Ann Oncol
|
2001
|
0.95
|
|
27
|
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
|
Br J Cancer
|
2009
|
0.94
|
|
28
|
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
|
Eur J Cancer
|
2001
|
0.92
|
|
29
|
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2003
|
0.92
|
|
30
|
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
|
Ann Oncol
|
2004
|
0.92
|
|
31
|
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.
|
Eur J Cancer
|
2009
|
0.91
|
|
32
|
Leptomeningeal infiltration in esthesioneuroblastoma: report of two cases with poor prognosis.
|
Eur Neurol
|
1994
|
0.91
|
|
33
|
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
|
J Clin Oncol
|
2002
|
0.91
|
|
34
|
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
|
Ann Oncol
|
2005
|
0.90
|
|
35
|
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
|
Ann Oncol
|
2012
|
0.90
|
|
36
|
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
|
Eur J Cancer
|
2005
|
0.90
|
|
37
|
Phase II study of E7070 in patients with metastatic melanoma.
|
Ann Oncol
|
2005
|
0.90
|
|
38
|
Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.
|
Cancer Res
|
1989
|
0.89
|
|
39
|
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
|
Ann Oncol
|
2003
|
0.89
|
|
40
|
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
|
Ann Oncol
|
2003
|
0.89
|
|
41
|
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.
|
Br J Cancer
|
2010
|
0.88
|
|
42
|
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
|
Cancer Chemother Pharmacol
|
1990
|
0.87
|
|
43
|
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
|
Eur J Cancer
|
2003
|
0.87
|
|
44
|
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
|
Br J Cancer
|
1996
|
0.87
|
|
45
|
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
|
J Clin Oncol
|
1999
|
0.86
|
|
46
|
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
|
Eur J Cancer
|
2002
|
0.85
|
|
47
|
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.
|
Eur J Cancer
|
2003
|
0.85
|
|
48
|
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
|
Br J Cancer
|
2006
|
0.84
|
|
49
|
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
|
Br J Cancer
|
2012
|
0.84
|
|
50
|
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
|
J Clin Oncol
|
1996
|
0.84
|
|
51
|
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
|
Br J Cancer
|
2012
|
0.84
|
|
52
|
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
|
Ann Oncol
|
2002
|
0.83
|
|
53
|
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
|
Br J Cancer
|
2007
|
0.82
|
|
54
|
Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
|
Cancer Chemother Pharmacol
|
2007
|
0.82
|
|
55
|
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
|
Am J Clin Oncol
|
2001
|
0.82
|
|
56
|
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
|
Eur J Cancer
|
2003
|
0.82
|
|
57
|
Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastasis.
|
Eur J Cancer
|
1981
|
0.82
|
|
58
|
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
|
Eur J Cancer
|
2004
|
0.82
|
|
59
|
Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
|
Breast Cancer Res Treat
|
2004
|
0.81
|
|
60
|
Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
|
Ann Oncol
|
2001
|
0.81
|
|
61
|
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
|
Eur J Cancer
|
2004
|
0.80
|
|
62
|
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.
|
Eur J Cancer
|
2001
|
0.80
|
|
63
|
Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.
|
Semin Oncol
|
1996
|
0.80
|
|
64
|
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
|
Eur J Cancer
|
2002
|
0.80
|
|
65
|
Docetaxel in combination with doxorubicin or vinorelbine.
|
Eur J Cancer
|
1997
|
0.80
|
|
66
|
An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Ann Oncol
|
1998
|
0.79
|
|
67
|
Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer.
|
Am J Clin Oncol
|
1990
|
0.79
|
|
68
|
A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
|
Clin Cancer Res
|
1999
|
0.79
|
|
69
|
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
|
Cancer Chemother Pharmacol
|
2006
|
0.79
|
|
70
|
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
|
Cancer Treat Rev
|
2005
|
0.79
|
|
71
|
[Management of metastatic HER2-positive breast cancer: present and future].
|
Bull Cancer
|
2010
|
0.78
|
|
72
|
Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genes.
|
Int J Cancer
|
2000
|
0.78
|
|
73
|
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.
|
Eur J Cancer
|
2002
|
0.78
|
|
74
|
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
|
Ann Oncol
|
1994
|
0.78
|
|
75
|
Taxoids in combination chemotherapy for metastatic breast cancer.
|
Anticancer Drugs
|
1996
|
0.78
|
|
76
|
Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, Saclay.
|
Ann Oncol
|
1993
|
0.77
|
|
77
|
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
|
Eur J Cancer
|
1993
|
0.77
|
|
78
|
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.77
|
|
79
|
Phase II clinical evaluation of doxifluridine.
|
Cancer Treat Rep
|
1986
|
0.77
|
|
80
|
Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
|
Ann Oncol
|
2001
|
0.77
|
|
81
|
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
|
Cancer Chemother Pharmacol
|
2000
|
0.77
|
|
82
|
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.
|
Ann Oncol
|
2009
|
0.76
|
|
83
|
Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
84
|
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.
|
Br J Cancer
|
2011
|
0.76
|
|
85
|
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.
|
J Neurooncol
|
2000
|
0.76
|
|
86
|
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.
|
Eur J Cancer
|
1998
|
0.75
|
|
87
|
Docetaxel and cisplatin in head and neck cancer.
|
Ann Oncol
|
2000
|
0.75
|
|
88
|
[Use of radio-labelled monoclonal antibodies for the scintigraphic detection of human colorectal cancers].
|
Bull Cancer
|
1983
|
0.75
|
|
89
|
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
|
Br J Clin Pharmacol
|
2002
|
0.75
|
|
90
|
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
|
Clin Ter
|
1994
|
0.75
|
|
91
|
[Bone metastasis revealing a hepatoma. 13 cases].
|
Rev Rhum Mal Osteoartic
|
1981
|
0.75
|
|
92
|
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
|
Eur J Cancer
|
2004
|
0.75
|
|
93
|
Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
|
Tumour Biol
|
1984
|
0.75
|
|
94
|
[Bone tumors. Case 5: osteoblastoma].
|
Ann Radiol (Paris)
|
1984
|
0.75
|
|
95
|
The EORTC and drug development. European Organisation for Research and Treatment of Cancer.
|
Eur J Cancer
|
2002
|
0.75
|
|
96
|
[Endomyocardial biopsy as a method of surveilling adriamycin cardiac toxicity. 28 biopsies in 26 patients].
|
Arch Mal Coeur Vaiss
|
1983
|
0.75
|
|
97
|
[Phase II trial of pepleomycin in metastatic cancer of the prostate].
|
Bull Cancer
|
1986
|
0.75
|
|
98
|
[Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
|
Rev Pneumol Clin
|
2000
|
0.75
|
|
99
|
Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.
|
Ann Oncol
|
2002
|
0.75
|
|
100
|
[Comparison of the cardiotoxicity of adriamycin and aclacinomycin A in the rat. Optical and electron microscopic study].
|
Arch Mal Coeur Vaiss
|
1983
|
0.75
|
|
101
|
Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.
|
Int J Cancer
|
1999
|
0.75
|
|
102
|
Reproducibility of image interpretation in immunoscintigraphy performed with indium-111- and iodine-131-labeled OC125 F(ab')2 antibody injected into the same patients.
|
J Nucl Med
|
1991
|
0.75
|
|
103
|
Complementary roles of immunoscintigraphy and ultrasonography.
|
Eur J Nucl Med
|
1985
|
0.75
|
|
104
|
Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.
|
Eur J Cancer
|
1996
|
0.75
|
|
105
|
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
|
Melanoma Res
|
1999
|
0.75
|
|
106
|
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
|
Cancer Chemother Pharmacol
|
2011
|
0.75
|
|
107
|
Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.
|
Eur J Cancer
|
1993
|
0.75
|
|
108
|
EORTC/GTO adjuvant chemotherapy program for primary Ewing's sarcoma: results at 5 years.
|
Recent Results Cancer Res
|
1978
|
0.75
|
|
109
|
[Intraperitoneal administration of interferon gamma. An efficient adjuvant to the chemotherapy of ovarian cancers. Apropos of an European study of 108 patients].
|
Bull Cancer
|
1993
|
0.75
|
|
110
|
Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.
|
Cancer Chemother Pharmacol
|
1995
|
0.75
|
|
111
|
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
|
Invest New Drugs
|
2004
|
0.75
|
|
112
|
Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
|
Drugs Exp Clin Res
|
1986
|
0.75
|
|
113
|
Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.
|
Eur J Cancer
|
1992
|
0.75
|
|
114
|
[Non-invasive methods in the monitoring of patients treated with adriamycin].
|
Arch Mal Coeur Vaiss
|
1981
|
0.75
|
|
115
|
Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.
|
Eur J Cancer Care (Engl)
|
2013
|
0.75
|
|
116
|
Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.
|
Cancer Invest
|
2003
|
0.75
|
|
117
|
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group].
|
Pathol Biol (Paris)
|
1992
|
0.75
|
|
118
|
Pirarubicin in advanced breast cancer: a French cooperative phase II study.
|
Eur J Cancer
|
1990
|
0.75
|
|
119
|
Fotemustine plus dacarbazine for malignant melanoma.
|
Eur J Cancer
|
1992
|
0.75
|
|
120
|
[Intestinal endosalpingiosis. Apropos of 2 cases].
|
Ann Chir
|
1995
|
0.75
|
|
121
|
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching.
|
Eur J Cancer
|
2012
|
0.75
|
|
122
|
Anti-beta HCG abdominopelvic immunoscintigraphy in patients with resistant gestational trophoblastic disease.
|
Nucl Med Commun
|
1992
|
0.75
|
|
123
|
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
|
Invest New Drugs
|
2012
|
0.75
|
|
124
|
[Primary heteroplastic dysgerminomas and dysembryomas of the mediastinum. Proposals on management].
|
Ann Chir
|
1986
|
0.75
|
|
125
|
[Report on pure non-seminomatous germinal tumors of the mediastinum].
|
Ann Chir
|
1986
|
0.75
|
|
126
|
[Adjuvant treatment of osteosarcomas. Experience of the Group for the Study of Bone Tumors].
|
Rev Chir Orthop Reparatrice Appar Mot
|
1987
|
0.75
|
|
127
|
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
|
Breast Cancer Res Treat
|
1992
|
0.75
|